Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 16/20 | 0.36 |
| ▸ | ABL1 | P00519 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22410812 | 0.93 | P2RX7 (0.37) | P2RX7ABL1TRPV4 | |
| SCHEMBL22410811 | 0.93 | P2RX7 (0.37) | P2RX7ABL1TRPV4 | |
| SCHEMBL22424211 | 0.92 | P2RX7 (0.36) | P2RX7ABL1TRPV4 | |
| SCHEMBL25051697 | 0.91 | P2RX7 (0.36) | P2RX7ABL1TRPV4 | |
| SCHEMBL22423962 | 0.91 | P2RX7 (0.36) | P2RX7ABL1TRPV4 | |
| SCHEMBL22424125 | 0.91 | P2RX7 (0.36) | P2RX7ABL1TRPV4 | |
| SCHEMBL22424304 | 0.91 | P2RX7 (0.36) | P2RX7ABL1 | |
| SCHEMBL22424236 | 0.90 | P2RX7 (0.35) | P2RX7ABL1TRPV4 | |
| SCHEMBL22424579 | 0.90 | P2RX7 (0.35) | P2RX7ABL1LMNATRPV4 | |
| SCHEMBL22424588 | 0.90 | P2RX7 (0.35) | P2RX7ABL1LMNATRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113710667-A | Fused cyclic pyrimidinone derivatives for the treatment of HBV infection or HBV induced diseases | 爱尔兰詹森科学公司 | 2021-11-26 | — | — | CN | disclosed |
| WO-2020182990-A1 | FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-09-17 | — | — | WO | disclosed |